Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado 2002

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

por de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Publicado 1999

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

por Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publicado 2018